ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

17 links0 made here, not in the record29 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05395052FT536 Monotherapy and inCombination With MonoclonalAntibodies in AdvancedSolid TumorsFate TherapeuticsPhase 1 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionColorectal NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termBreast NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termOvarian NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termPancreatic NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termHead and Neck NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSAllogeneic iPSC-derived Ant…Entry “FT536”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCyclophosphamideIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundFludarabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundInterleukin-2Entry “IL-2”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAvelumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerCetuximabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAmivantamabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Allogeneic iPSC-derived Anti-MICA/B CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT536

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “FT536”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Allogeneic iPSC-derived Anti-MICA/B CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT536Claude Opus 5.5TestedCurrent
Nov 2CyclophosphamideClaude Opus 5.5BackgroundCurrent
Nov 2FludarabineClaude Opus 5.5BackgroundCurrent
Nov 2Interleukin-2Claude Opus 5.5BackgroundCurrent
Nov 2AvelumabClaude Opus 5.5BackgroundCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 2AtezolizumabClaude Opus 5.5Background · partnerCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · partnerCurrent
Nov 2CetuximabClaude Opus 5.5BackgroundCurrent
Nov 2AmivantamabClaude Opus 5.5BackgroundCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14Colorectal NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Breast NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Ovarian NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Pancreatic NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Head and Neck NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18Allogeneic iPSC-derived Anti-MICA/B CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT536Rule based · role ruleTestedAgrees
Nov 18CyclophosphamideRule based · role ruleBackgroundAgrees
Nov 18FludarabineRule based · role ruleBackgroundAgrees
Nov 18Interleukin-2Rule based · role ruleBackgroundAgrees
Nov 18AvelumabRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18AtezolizumabRule based · role ruleBackgroundAgrees
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
Nov 18CetuximabRule based · role ruleBackgroundAgrees
Nov 18AmivantamabRule based · role ruleBackgroundAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.